摘要
目的 探讨复方苦参注射液(compound Kushen injection,CKI)辅助甲磺酸奥希替尼片治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效及其安全性。方法 选取2021年6月至2024年8月鄂州市中医医院NSCLC患者98例。根据随机数字表法,将患者分为对照组(n=47)和观察组(n=51)。对照组采用甲磺酸奥希替尼片治疗,口服,1次/d,6周为1个疗程,共治疗2个疗程。观察组在对照组基础上给予CKI,静脉注射,20 ml/(次·d),连续用药14 d、停药7 d,21 d为1个疗程,共治疗4个疗程。比较两组患者治疗前后临床疗效、肿瘤标志物水平、T淋巴细胞亚群、生活质量卡氏功能状态评分(Karnofskyperformancestatus,KPS)、血常规、D-二聚体和不良反应发生情况。结果 98例患者中,男64例、女34例,年龄39~81岁,平均(67.3±8.9)岁。治疗后,观察组总缓解率和疾病控制率高于对照组(82.35%比59.57%,90.19%比72.34%);肿瘤标志物、D-二聚体低于对照组;T淋巴细胞亚群整体水平及KPS高于对照组;对照组WBC低于治疗前,观察组高于治疗前,且观察组高于对照组;总不良反应及胃肠道反应发生率低于对照组,差异均有统计学意义(P<0.05)。结论 CKI辅助甲磺酸奥希替尼片治疗NSCLC近期临床疗效较好,可提高抗肿瘤作用、增强免疫功能水平、调节D-二聚体水平,安全性较好。
Objective To explore the clinical efficacy and safety of compound Kushen injection(CKI)assisted with oxitinib mesylate tablets in the treatment of non-small cell lung cancer(NSCLC).Methods A total of 98 patients with NSCLC in Ezhou Hospital of Traditional Chinese Medicine from June 2021 to August 2024 were selected,and were divided into control group(n=47)and observation group(n=51)according to the random number table method.The control group was treated with oxytinib mesylate tablets,once a day,with six weeks as a course of treatment,with a total of two courses of treatment.On the basis of the control group,the observation group was given CKI,intravenous injection,20 ml/(time·d),continuous medication for 14 days,drug withdrawal for 7 days and 21 days as a course of treatment,with a total of four courses of treatment.The clinical efficacy,tumor marker level,T lymphocyte subsets,Karnofsky performance status(KPS)of quality of life,blood routine,D-dimer and adverse reactions were analyzed in the two groups before and after treatment.Results Among the 98 patients,there were 64 males and 34 females,aged from 39 to 81 years,with an average of(67.3±8.9)years.After treatment,the overall response rate and disease control rate in the observation group were higher than those in the control group(82.35%vs.59.57%,90.19%vs.72.34%).Tumor markers and D-dimer were lower than those in the control group.The overall level of T lymphocyte subsets and KPS were higher than those of the control group.The WBC of the control group was lower than that before treatment,the observation group was higher than that before treatment,and the observation group was higher than that of the control group.The incidence of total adverse reactions and gastrointestinal reactions was lower than that of the control group,and the differences were statistically significant(P<0.05).Conclusions CKI assisted with oxitinib mesylate tablets has a good short-term clinical effect in the treatment of NSCLC,which can improve the anti-tumor effect,enhance the level of immune function and regulate the level of D-dimer,with good safety.
作者
刘佳乐
罗红梅
周娓
Liu Jiale;Luo Hongmei;Zhou Wei(Department of Oncology,Ezhou Hospital of Traditional Chinese Medicine,Ezhou 436000,China)
出处
《北京医学》
2025年第6期507-512,共6页
Beijing Medical Journal
基金
鄂州市科技计划项目基础研究及人才创新专项(EZ01-007-20240190)。
关键词
非小细胞肺癌
复方苦参注射液
甲磺酸奥希替尼片
临床疗效
不良反应
non-small cell lung cancer(NSCLC)
compound Kushen injection(CKI)
oxytinib mesylate tablets
clinical efficacy
adverse effect
